The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2018 | More evidence needed to support checkpoint inhibitor use in late-stage cancer
Giorgio Scagliotti, MD, PhD, of the University of Torino, Torino, Italy, discusses the considerable improvement in progression free survival (PFS) in a small subgroup of non-small cell lung cancer (NSCLC) patients on immune checkpoint inhibitors. Pembrolizumab alone seemed to be superior to chemotherapy for high PD-L1 expressing tumors. Bringing attention to insufficient evidence, Dr Scagliotti proposes that a diverse therapeutic portfolio is critical to managing and treating stage 4 disease. This interview was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.
